✉️ Email Us
📞 +91-6262 800 800

appointments@aarvyhealthcare.com

Aarvy Healthcare, Sector 90, Gurgaon, Haryana 122505

24-Hour Emergency Aid
Call Us 24/7
+91-62 62 800 800

Aarvy Healthcare, Sector 90, Gurgaon, Haryana 122505

Receive Directions
Book An Appointment
Book An Appointment

Dr. Pradeep Kumar Thapa

Best Nuclear Medicine Doctor in Gurgaon

24/7 Support:
+91-62 62 800 800
favicon logo

Dr. Pradeep Kumar Thapa

Oncology

+ 91-62 62 800 800
appointments@aarvyhealthcare.com
Sector 90, Gurgaon, Haryana 122505
Appointment With Doctor
Get Virtual Care

Introducing the Doctor

Nationality:    Indian

Speciality:      Oncology  

OPD Timings :    Monday To Saturday 9:00 AM – 5:00 PM   

Dr. Pradeep Thapa is a Sr. Consultant, Nuclear Medicine, associated with American Oncology Institute at Aarvy Healthcare, Gurgaon. 

Dr. Thapa has been trained in the field of Nuclear Medicine with over 12 years of overall work experience. His expertise lie in diagnosis and therapy through Nuclear Medicine. 

Dr. Thapa has been extensively trained at the best medical schools across India. He graduated from the prestigious T.N. Medical College, Mumbai, followed by a Diploma in Radiation Medicine from the Institute of Nuclear Medicine and Allied Sciences, Delhi University. He further completed his D.N.B. from Radiation Medicine Centre, Mumbai, followed by a Fellowship from European Board of Nuclear Medicine (FEBNM).

He has to his credit many research papers published across national and international journals. His papers at various Nuclear Medicine forums and medical conferences make him the best nuclear medicine doctor in Gurgaon.

Medical Qualifications :

MBBS from TN Medical College, Mumbai Central, Mumbai -2007
DRM from Institute of Nuclear Medicine and Allied Sciences, Delhi University – 2010- 2012
DNB Nuclear medicine, Radiation Medicine Centre, Mumbai – 2013-2015
Fellow European Board of Nuclear Medicine (FEBNM) – October 2018

Areas of Expertise :

Dr Thapa has worked extensively on PET CT, SPECT-CT & Gamma Camera systems, with experience in managing patients with thyroid disorders, including radio-iodine therapy treatment. Reading and interpretation of PET CT, Gamma camera, SPECT CT scan, including new PET tracers Ga-68 DOTANOC and Ga-68 PSMA.
Also has an experience in administrating radionuclides for Nuclear Medicine Therapy using Lutetium DOTANOC for Neuroendocrine tumours, I-131 for Carcinoma Thyroid, Sm-153 EDTMP and Lu-177 EDTMP for bone pain palliation and Iodine 131 MIBG for Metastatic Inoperable Neuroblastomas, Paraganglioma, Carcinoid Tumours and Pheochromocytomas & Lutetium 177 PSMA for Metastatic Prostate Cancer.

Professional Membership:

Member of European Association of Nuclear Medicine.
Member of Society of Nuclear Medicine, India.

Awards & Accolades :

Recipient of Alavi-Mandell Award for publication titled “Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases”.
Best poster recipient for “Comparative study between Tc-99m Methionine and C-11 Methionine in detection of recurrence in primary brain tumor” at Annual Conference of Society of Nuclear Medicine, India, 2011.

Publications :

Thapa P, Basu S. Leveraging the power of non-radium radionuclide treatments in bone metastases. Q J Nucl Med Mol Imaging. 2019 Jul 1.
Basu S, Chakraborty S, Parghane RV, Kamaldeep, Ranade R, Thapa P. One decade of ‘Bench-to-Bedside’ peptide receptor radionuclide therapy with indigenous [ 177 Lu] Lu-DOTATATE obtained through ‘Direct’ neutron activation route: lessons learnt including practice evolution in an Indian setting. Am J Nucl Med Mol Imaging. 2020 Aug 25;10(4):178-211.
Thapa P, Kalshetty A, Basu S. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary: A subgroup-specific analysis based on clinical presentation. World J Nucl Med. 17(4):219-222. Oct-Dec 2017.
Dutta D, Pandey RK, Gogoi R, Solanki N, Madan R, Mondal A, Dogra S, Thapa P. Occult phosphaturic mesenchymal tumour of femur cortex causing oncogenic osteomalacia – diagnostic challenges and clinical outcomes. Endokrynol Pol. 69(2):205-210. 2018.
Thapa P, Parghane R, Basu S. 177-Lu DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites. World J Nucl Med. 16(3):223-228. Jul-Sep 2017.
Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare